Streetwise Medical Devices Articles


Agreement Facilitates Progress Toward Medical Device Approvals

  ()
This medical device company enters a partnership to provide quality and regulatory services. read more >

Coverage Initiated on Developer of Women's Reproductive Health Products

Research Report
  ()
A ROTH Capital Partners research report outlined the key drivers of the investment thesis for this firm. read more >

Analyst: 'New CEO, Larger Sales Team and Greater SUI Focus Should Help Medical Device Growth'

Research Report
  ()
Cowen analyst Dr. Joshua Jennings highlighted this medical device firm’s Q1/18 developments and financial results. read more >

What Stephen Hawking Missed: Small Biotechs Developing Promising Cell Therapies for Devastating Disease

  ()
In the second of a two-part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small-cap companies targeting big-ticket indications and their potential to drive blockbuster value for both patients and investors. read more >

Medical Device Firm Posts 'Strong Performance' Globally in Q4/17

Research Report
  ()
The company performed strongly in the U.S. and the Asia Pacific region. read more >

Convergence Will Drive the Ultimate Disruption of Life Sciences

Contributed Opinion
  ()
Andrea Bartzen, a strategic commercial and communication consultant, describes the disruptive technologies positioned to radically alter the business of life sciences as discussed at a recent BIO CEO Summit Investor Night. read more >

Medical Device Firm to Launch Trials for Treatment Targeting $12 Billion Incontinence Market

Research Report
  ()
Anthony Vendetti, an analyst with Maxim Group, shared the results both of a pilot study for stress urinary incontinence and of a recent equity raise by this company. read more >

Medical Device Firm Boosts Quarterly Revenue 50% YOY

Research Report
  ()
A Maxim Group report noted the recently announced revenue achieved and anticipated by this producer of cancer treatment devices. read more >
Showing Results: 1 to 8 of 8

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"We are initiating coverage on PMN." ❭
– John Vandermosten, Zacks Small-Cap Research
"SPR's acquisition in the pipeline creates water-soluble cannabis." ❭
– Chris Parry, Equity Guru
"We continue to view DRRX as undervalued and reiterate our Buy rating." ❭
– Francois Brisebois, Laidlaw & Company